Utilizing Microbes to Treat Naturally Occurring Cancer in Veterinary Species

Withers, Sita S.; Sparger, Ellen E.; Boudreaux, Bonnie; Mason, Nicola J.

doi:10.1007/s40588-019-00130-7

Cited by 2 publications

(3 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparative oncology reviews (Anderson & Modiano, 2015;Beck et al, 2022;Bentley et al, 2017;Burton & Khanna, 2014;Dias et al, 2021;Finocchiaro & Glikin, 2017;Garden et al, 2018;Gardner et al, 2016;Gingrich et al, 2019;Giuliano, 2021;Gordon & Khanna, 2010;Kieslinger et al, 2019;Kleber et al, 2022;LeBlanc & Mazcko, 2020;Lollini et al, 2013;Mestrinho & Santos, 2021;Nickoloff et al, 2017;Oh & Cho, 2023;Page et al, 2016;Pinard et al, 2022;Porrello et al, 2004Porrello et al, , 2006Rahman et al, 2023;Regan et al, 2018;Riccardo et al, 2015;Vafaei et al, 2022;Vail & Thamm, 2000.;Vanhaezebrouck & Scarpelli, 2023;Withers et al, 2019;Withrow & Wilkins, 2010) Cell therapy review (Arzi et al, 2021) Thesis (Gruen, 2016) Ethical review (Bertout et al, 2021) One Health reviews (Arzi et al, 2022;Kol et al, 2015) Perianal fistulas review (Burdzinska et al, 2022) Osteoarthritis (Cimino Brown, 2017) Pain reviews (Iadarola et al, 2021;Lascelles et al, 2018Lascelles et al, , 2022 Cachex...…”

Section: Gliomasmentioning

confidence: 99%

The Integration of Community-Dwelling Non-Human Companion Animals in Research Programs

Medrano,

Carver

2024

OHI

View full text Add to dashboard Cite

Traditional purpose-bred laboratory animals used in clinical research and testing often do not represent human conditions, with efficacy results often not replicated in human clinical trials. Quality of life among laboratory animals is generally low given exposure to painful procedures, pathologies, and unnatural living conditions. This form of research also contributes to several detrimental environmental effects including pollution, climate change, and altered biodiversity. A One Health solution to this issue involves replacing purpose-bred laboratory animals with companion animals in research given greater similarities to human genetic diversity, healthcare systems, and living environments. The integration of companion animals in this way can also mitigate the effects of research using purpose-bred laboratory animals on animals and the environment. Most published literature on the topic involves veterinary clinical trials evaluating the potential of companion animals as research models for future human applications. We propose a study to explore the perspectives of veterinarians and researchers within this field to better understand some of the strengths and challenges associated with utilizing companion animals in clinical research programs.

show abstract

Section: Gliomasmentioning

confidence: 99%

The Integration of Community-Dwelling Non-Human Companion Animals in Research Programs

Medrano,

Carver

2024

OHI

View full text Add to dashboard Cite

show abstract

“…Immunocidin ® is an immunomodulator derived from nonpathogenic mycobacterial cell wall fraction that is licensed for use intra-lesionally in canine mammary cancer. 94 Oncept ® is the most widely used immunotherapy for dogs. In addition to being available in the US and Canada it is also approved by the European Medicines Agency and is available in several other countries.…”

Section: Immunotherapies and Thermal Therapies In Canine Oncologymentioning

confidence: 99%

“…Currently, Blontress®, Immunocidin®, Oncept®, and Tactress® are the FDA‐approved or USDA‐licensed immunotherapies for dogs 93 ; Two of them are indicated for lymphoma treatment, monoclonal antibodies for CD20‐positive B cells (Blontress®) and for CD52‐positive T cells (Tactress®). Immunocidin® is an immunomodulator derived from non‐pathogenic mycobacterial cell wall fraction that is licensed for use intra‐lesionally in canine mammary cancer 94 . Oncept® is the most widely used immunotherapy for dogs.…”

Section: Immunotherapies and Thermal Therapies In Canine Oncologymentioning

confidence: 99%

Local tumour nanoparticle thermal therapy: A promising immunomodulatory treatment for canine cancer

Castelló

Carvalho

Bakuzis

et al. 2022

Vet Comparative Oncology

View full text Add to dashboard Cite

Distinct thermal therapies have been used for cancer therapy. For hyperthermia (HT) treatment the tumour tissue is heated to temperatures between 39 and 45°C, while during ablation (AB) temperatures above 50°C are achieved. HT is commonly used in combination with different treatment modalities, such as radiotherapy and chemotherapy, for better clinical outcomes. In contrast, AB is usually used as a single modality for direct tumour cell killing. Both thermal therapies have been shown to result in cytotoxicity as well as immune response stimulation. Immunogenic responses encompass the innate and adaptive immune systems and involve the activation of macrophages, dendritic cells, natural killer cells and T cells. Several heat technologies are used, but great interest arises from nanotechnology‐based thermal therapies. Spontaneous tumours in dogs can be a model for cancer immunotherapies with several advantages. In addition, veterinary oncology represents a growing market with an important demand for new therapies. In this review, we will focus on nanoparticle‐mediated thermal‐induced immunogenic effects, the beneficial potential of integrating thermal nanomedicine with immunotherapies and the results of published works with thermotherapies for cancer using dogs with spontaneous tumours, highlighting the works that evaluated the effect on the immune system in order to show dogs with spontaneous cancer as a good model for evaluated the immunomodulatory effect of nanoparticle‐mediated thermal therapies.

show abstract

Utilizing Microbes to Treat Naturally Occurring Cancer in Veterinary Species

Cited by 2 publications

References 81 publications

The Integration of Community-Dwelling Non-Human Companion Animals in Research Programs

The Integration of Community-Dwelling Non-Human Companion Animals in Research Programs

Local tumour nanoparticle thermal therapy: A promising immunomodulatory treatment for canine cancer

Contact Info

Product

Resources

About